Cargando…

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

Using combined endpoints to define no evident disease activity (NEDA) is becoming increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS). Historically, NEDA has taken account of the occurrence of relapses, brain magnetic resonance imaging (MRI) lesions and disabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giovannoni, Gavin, Tomic, Davorka, Bright, Jeremy R, Havrdová, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Topical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536258/ https://www.ncbi.nlm.nih.gov/pubmed/28381105 http://dx.doi.org/10.1177/1352458517703193

Ejemplares similares

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
por: Nixon, Richard, et al.
Publicado: (2014)

The Multiple Sclerosis Care Unit
por: Soelberg Sorensen, Per, et al.
Publicado: (2018)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

In vivo imaging of chronic active lesions in multiple sclerosis
por: Calvi, Alberto, et al.
Publicado: (2020)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Decentralised clinical trials in multiple sclerosis research
por: Garjani, Afagh, et al.
Publicado: (2022)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review
por: Alexander, Sarah, et al.
Publicado: (2020)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
por: Havrdova, E., et al.
Publicado: (2017)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity
por: Hegen, Harald, et al.
Publicado: (2022)

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis
por: Arnason, Barry G, et al.
Publicado: (2013)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Pregnancy, sex and hormonal factors in multiple sclerosis
por: Miller, David H, et al.
Publicado: (2014)

Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years
por: Hawton, Annie, et al.
Publicado: (2020)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
por: Reyes, Saúl, et al.
Publicado: (2021)

Neuromodulation for functional bladder disorders in patients with multiple sclerosis
por: Rahnama’i, Mohammad Sajjad
Publicado: (2019)

Is Clostridium perfringens epsilon toxin associated with multiple sclerosis?
por: Titball, Richard W, et al.
Publicado: (2023)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Multiple Sclerosis and Its Treatment
por: Giovannoni, Gavin, et al.
Publicado: (1999)

Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review
por: Bove, Riley, et al.
Publicado: (2021)

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
por: Reder, Anthony T, et al.
Publicado: (2022)

What’s in a name? That which we call Multiple Sclerosis Fatigue
por: Hubbard, Amy Lynn, et al.
Publicado: (2020)

Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects
por: Olbert, Elisabeth, et al.
Publicado: (2022)

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
por: Bennett, JL, et al.
Publicado: (2015)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review
por: Karim, Mohammad Ehsanul, et al.
Publicado: (2020)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Predicting Multiple Sclerosis: Challenges and Opportunities
por: Hone, Luke, et al.
Publicado: (2022)

Real-Life Outcome in Multiple Sclerosis in the Czech Republic
por: Kobelt, Gisela, et al.
Publicado: (2019)

Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms
por: Heitmann, Henrik, et al.
Publicado: (2020)

No evidence for an association between alcohol consumption and Multiple Sclerosis risk: a UK Biobank study
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study
por: Kalincik, Tomas, et al.
Publicado: (2012)

The potential of serum neurofilament as biomarker for multiple sclerosis
por: Bittner, Stefan, et al.
Publicado: (2021)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis
por: Khanna, Surabhi Agarwal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hn60628sgo88884ru403uvqhlp